Semi-synthetic Artemisinin: A New Source of Artemisinin to Reduce Barriers to ACT Access November...

11
Semi-synthetic Artemisinin: A New Source of Artemisinin to Reduce Barriers to ACT Access November 18, 2008 London, UK Presented By Philippe Desjeux, PhD

Transcript of Semi-synthetic Artemisinin: A New Source of Artemisinin to Reduce Barriers to ACT Access November...

Page 1: Semi-synthetic Artemisinin: A New Source of Artemisinin to Reduce Barriers to ACT Access November 18, 2008 London, UK Presented By Philippe Desjeux, PhD.

Semi-synthetic Artemisinin: A New Source of Artemisinin to Reduce Barriers to ACT Access

November 18, 2008London, UK

Presented By Philippe Desjeux, PhD

Page 2: Semi-synthetic Artemisinin: A New Source of Artemisinin to Reduce Barriers to ACT Access November 18, 2008 London, UK Presented By Philippe Desjeux, PhD.

2

iOWH Mission

The Institute for OneWorld Health Develops Safe, Effective, and Affordable

New Medicines for People with Infectious Diseases in the Developing World

Page 3: Semi-synthetic Artemisinin: A New Source of Artemisinin to Reduce Barriers to ACT Access November 18, 2008 London, UK Presented By Philippe Desjeux, PhD.

3

The Partnership

Page 4: Semi-synthetic Artemisinin: A New Source of Artemisinin to Reduce Barriers to ACT Access November 18, 2008 London, UK Presented By Philippe Desjeux, PhD.

4

Project Vision: Semi-synthetic Artemisinin

Increase Increase Access to ACT Access to ACT

CuresCures

Global Health Challenges

(Artemisinin Supply)

SyntheticBiology

(Biotechnology)

Page 5: Semi-synthetic Artemisinin: A New Source of Artemisinin to Reduce Barriers to ACT Access November 18, 2008 London, UK Presented By Philippe Desjeux, PhD.

5

Semi-Synthetic Artemisinin Project Goals

Create a complementary source of non-seasonal, high-quality and affordable artemisinin to supplement the current plant-derived supply

Contribute to stabilizing the price of artemisinin to benefit all stakeholders

Ensure semi-synthetic artemisinin is available to all high-quality derivatizers and ACT manufacturers

Enable millions of people infected with malaria to gain consistent access to affordable, high-quality, life-saving ACTs

Page 6: Semi-synthetic Artemisinin: A New Source of Artemisinin to Reduce Barriers to ACT Access November 18, 2008 London, UK Presented By Philippe Desjeux, PhD.

6

A Second Source Supplements & Stabilizes the Artemisinin Supply Chain

O

O

O

OO

H

HHHO

O

H

H

H

Chemistry

ArtemisininArtemisinic Acid

Yeast+

Sugar

Fermentation

DERIVATIVES

ACT Therapy

O

O

O

OO

H

HH

Artemisinin

ExtractionCultivation

Months

Days

Controlled Process

Page 7: Semi-synthetic Artemisinin: A New Source of Artemisinin to Reduce Barriers to ACT Access November 18, 2008 London, UK Presented By Philippe Desjeux, PhD.

7

Artemisinin As A Starting Material

Artemisinin

Dihydroartemisinin

Artesunate

Artemether

Artelinate

Arteether

Artemisinic acid

Raw material Defined specifications

Starting materialDefined specifications

API Compendial specifications

GMP manufacturing

Page 8: Semi-synthetic Artemisinin: A New Source of Artemisinin to Reduce Barriers to ACT Access November 18, 2008 London, UK Presented By Philippe Desjeux, PhD.

8

Achievements & GoalsAchievements

• Completed strain engineering to reach productivity targets at bench scale fermenter level

• Transferred technology (fermentation, purification, and chemistry) to manufacturing partner

• Reproduced laboratory data at pilot scale

Goals• Demonstrate chemical comparability between semi-

synthetic and plant derived artemisinin No need for bioequivalence studies

• Process optimization and development of industrial processes suitable for 100,000L scale

Page 9: Semi-synthetic Artemisinin: A New Source of Artemisinin to Reduce Barriers to ACT Access November 18, 2008 London, UK Presented By Philippe Desjeux, PhD.

10

Semi-synthetic Artemisinin Timeline

Process Development and

Scale up

Industrialization

2011 - 2012

Pre-Development

10,000L1000L 100,000L

CommercialProduction

2nd Source of Artemisinin for ACTs

Page 10: Semi-synthetic Artemisinin: A New Source of Artemisinin to Reduce Barriers to ACT Access November 18, 2008 London, UK Presented By Philippe Desjeux, PhD.

11

Market Impact

Supplement botanical supply to support projected increased demand for ACTs

Semi-synthetic artemisinin cost is anticipated to be comparable to the current cost of high quality field production

Semi-synthetic artemisinin will be made broadly available to those derivative and ACT manufacturers who will apply the principle of “no profit, no loss”

Page 11: Semi-synthetic Artemisinin: A New Source of Artemisinin to Reduce Barriers to ACT Access November 18, 2008 London, UK Presented By Philippe Desjeux, PhD.

12

Thank You